01 · THE CUSTOMER PROBLEM
Wound developers often need hemostasis, fluid handling, microbial-barrier performance and tissue compatibility from the same product architecture.
Mykito matches the chitosan specification and physical format to the wound—fiber, nonwoven, sponge, film, coating or hydrogel—instead of supplying an undifferentiated powder.
Chitosan combines positive charge, film formation and form-factor versatility for internal and external wound-care development.
02 · RECOMMENDED STARTING POINT
Start with the material designed for the decision.
One polymer can be engineered into surgical hemostats, antimicrobial coatings and conformable dressings—then matched to the purity and absorption requirements of the intended wound environment.
Without the shell
Controlled fungal sourcing supports a traceable, non-animal supply strategy.
Specification engineered
MW, DDA, purity, charge density and format are selected around the target result.
Application ready
Powder is only the starting point; Mykito also develops films, fibers, gels, coatings and formulations.
One technical partner
Material selection, formulation support and the validation plan are connected from the first sample.
03 · PERFORMANCE TARGETS
Build toward outcomes a buyer can measure.
Surgical hemostats
Fibers, sponges and flowable matrices can be developed to concentrate blood components and support rapid clot formation.
Hemostatic + antibacterial systems
Chitosan-based constructs can combine bleeding control with an antibacterial barrier in a single material architecture.
Antimicrobial coatings
Thin films and coatings can add a functional surface to dressings, gauze and other wound-contact materials.
Application-ready forms
Hydrogels, sponges, films, coatings and fibers allow the format to follow the wound and clinical workflow.
04 · GO / NO-GO CRITERIA
Define the evidence before testing begins.
The first program is designed around three decision-making outputs—not an open-ended material trial.
Hemostatic performance
Antimicrobial or barrier performance
Fluid handling, sterilization and tissue compatibility
05 · FROM SAMPLE TO DECISION
A practical application program,
not a bag of powder.
Define
Agree on the function, baseline, constraints and measurable success criteria.
Screen
Select the MW, DDA, purity, dose and physical format that fit the application.
Validate
Test the winning system in the finished formulation, device, process or use environment.
Recommended first request: A wound-specific fiber, sponge, film or hydrogel selected for internal or external use.
Start the Sample Brief06 · WHY CHITOSAN
Charge + fluid-responsive architecture
Cationic interaction, fluid handling and matrix formation can be combined across fibers, sponges, films, coatings and hydrogels.
There is no universal concentration. Grade and dose are screened against pH, interacting ingredients, process conditions and the target performance profile.
Hemostasis, microbial-barrier performance, absorbency, tissue compatibility and sterilization are demonstrated in the finished wound product.